Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery
Launched by ULLEVAAL UNIVERSITY HOSPITAL · Oct 13, 2010
Trial Information
Current as of August 11, 2025
Terminated
Keywords
ClinConnect Summary
Single center, prospective, randomized parallel-group, double-blinded study
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • EF (ejection fraction)\<40%
- Exclusion Criteria:
- • renal failure, liver failure
About Ullevaal University Hospital
Ullevaal University Hospital, located in Oslo, Norway, is a leading healthcare institution renowned for its commitment to high-quality patient care, cutting-edge research, and clinical education. As a prominent clinical trial sponsor, the hospital engages in innovative studies across various medical disciplines, aiming to advance therapeutic options and improve health outcomes. With a multidisciplinary team of experienced researchers and clinicians, Ullevaal University Hospital fosters a collaborative environment that prioritizes ethical standards and patient safety while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Trial Officials
Knut A Kirkebøen, MD, PhD
Principal Investigator
Ullevaal University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials